

University of Massachusetts Medical School

eScholarship@UMMS

---

Neurobiology Publications and Presentations

Neurobiology

---

2013-09-03


## Deletions within its subcellular targeting domain enhance the axon protective capacity of Nmnat2 in vivo

Stefan Milde  
*Babraham Institute*

*Et al.*

Let us know how access to this document benefits you.

Follow this and additional works at: [https://escholarship.umassmed.edu/neurobiology\\_pp](https://escholarship.umassmed.edu/neurobiology_pp)

 Part of the [Neuroscience and Neurobiology Commons](#)

---

### Repository Citation

Milde S, Fox AN, Freeman MR, Coleman MP. (2013). Deletions within its subcellular targeting domain enhance the axon protective capacity of Nmnat2 in vivo. *Neurobiology Publications and Presentations*. <https://doi.org/10.1038/srep02567>. Retrieved from [https://escholarship.umassmed.edu/neurobiology\\_pp/178](https://escholarship.umassmed.edu/neurobiology_pp/178)

Creative Commons License



This work is licensed under a [Creative Commons Attribution-NonCommercial-Share Alike 3.0 License](#). This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in *Neurobiology Publications and Presentations* by an authorized administrator of eScholarship@UMMS. For more information, please contact [Lisa.Palmer@umassmed.edu](mailto:Lisa.Palmer@umassmed.edu).



## OPEN

Deletions within its subcellular targeting domain enhance the axon protective capacity of Nmnat2 *in vivo*Stefan Milde<sup>1</sup>, A. Nicole Fox<sup>2</sup>, Marc R. Freeman<sup>3</sup> & Michael P. Coleman<sup>1</sup><sup>1</sup>The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, United Kingdom, <sup>2</sup>Department of Neurobiology, University of Massachusetts Medical School, Worcester, MA 01605, United States, <sup>3</sup>Howard Hughes Medical Institute, Worcester, University of Massachusetts Medical School, Worcester, MA 01605, United States.

The NAD-synthesising enzyme Nmnat2 is a critical survival factor for axons *in vitro* and *in vivo*. We recently reported that loss of axonal transport vesicle association through mutations in its isoform-specific targeting and interaction domain (ISTID) reduces Nmnat2 ubiquitination, prolongs its half-life and boosts its axon protective capacity in primary culture neurons. Here, we report evidence for a role of ISTID sequences in tuning Nmnat2 localisation, stability and protective capacity *in vivo*. Deletion of central ISTID sequences abolishes vesicle association and increases protein stability of fluorescently tagged, transgenic Nmnat2 in mouse peripheral axons *in vivo*. Overexpression of fluorescently tagged Nmnat2 significantly delays Wallerian degeneration in these mice. Furthermore, while mammalian Nmnat2 is unable to protect transected *Drosophila* olfactory receptor neuron axons *in vivo*, mutant Nmnat2s lacking ISTID regions substantially delay Wallerian degeneration. Together, our results establish Nmnat2 localisation and turnover as a valuable target for modulating axon degeneration *in vivo*.

The NAD-synthesising enzyme Nmnat2 is a critical, endogenous survival factor for axons. Specific depletion of Nmnat2 in primary culture axons induces spontaneous degeneration that is rescued by expression of Wld<sup>S</sup>, suggesting a constant supply of Nmnat2 from the cell body into axons is required to ensure axon survival<sup>1</sup>. Similarly, peripheral nerve defects and neonatal mortality in Nmnat2 gene-trap mice are rescued by homozygous expression of Wld<sup>S</sup>, strongly suggesting a role for Nmnat2 in axon maintenance *in vivo*<sup>2</sup>. Due to its very short half-life, levels of Nmnat2 distal to an injury decline rapidly, prior to fast Wallerian degeneration<sup>1</sup>. Similarly, depletion of axonal Nmnat2 distal to an obstruction could account for degeneration when axonal transport is blocked. Delayed Wallerian degeneration, as achieved by expression of the Wld<sup>S</sup> protein<sup>3</sup> or by axonally targeted Nmnat1<sup>4,5</sup>, is the result, at least in part, of a much longer half-life of these Nmnat isoforms compared to Nmnat2, meaning that they can substitute the critical NAD-synthetic enzyme activity to keep axons alive despite the decline in levels of Nmnat2<sup>1</sup>. However, due to the requirement for ectopic expression of an introduced protein, the clinical usefulness of re-targeted forms of Nmnat1 (such as Wld<sup>S</sup>) is limited. In contrast, modulation of the turnover, enzymatic activity or delivery of the endogenous survival factor, Nmnat2, is a much more promising avenue to address axon degeneration during ageing and in disease. Further supporting a pro-survival function of Nmnat2 are its reported protective effects against injury-induced degeneration in live zebrafish<sup>6</sup> and mouse primary culture axons<sup>1,7</sup> as well as against neurodegeneration in a tauopathy mouse model<sup>8</sup>.

Nmnat2 is extremely labile, undergoes K48 poly-ubiquitination<sup>9</sup> and its turnover is at least partially mediated by the ubiquitin proteasome system<sup>1</sup>. Accordingly, inhibition of the ubiquitin proteasome system delays the onset of Wallerian degeneration in cut primary culture axons<sup>10</sup>, potentially by stabilising Nmnat2 levels. Additionally, a recent study reported *Drosophila* Nmnat (dNmnat) as a potential downstream target of the E3 ubiquitin ligase Highwire. In the absence of Highwire, dNmnat as well as transgenic mouse Nmnat2 are stabilised, resulting in significant protection of injured axons<sup>11</sup>. Furthermore, there is recent evidence showing that the mammalian homologue of Highwire, Phr1, regulates turnover of Nmnat2 in mammalian axons. Loss of Phr1 leads to increased levels of virally-transduced Nmnat2 and delays axon degeneration after injury in mouse peripheral axons<sup>12</sup>. Thus, modulation of Nmnat2 turnover presents a potentially promising target for delaying axon degeneration.

We recently reported that Nmnat2 is transported into primary culture axons by means of a Golgi-derived axonal transport vesicle population with which it associates through palmitoylation of a double-cysteine motif. This palmitoylation site is located in the exon 6-encoded region of Nmnat2, at the centre of the isoform-specific targeting and interaction domain (ISTID)<sup>13</sup>. Interestingly, however, we found that dissociation from transport

## SUBJECT AREAS:

MOLECULAR  
NEUROSCIENCECELL DEATH IN THE NERVOUS  
SYSTEM

CELLULAR NEUROSCIENCE

NEURODEGENERATION

Received

13 June 2013

Accepted

16 August 2013

Published

2 September 2013

Correspondence and  
requests for materials  
should be addressed toM.P.C. (michael.  
coleman@babraham.  
ac.uk)



vesicles through loss or mutation of the central, exon 6-encoded ISTID region enhances the ability of overexpressed Nmnat2 to preserve primary culture neurites after axotomy. This increased protective capacity was at least in part due to reduced levels of ubiquitination and an increased half-life of mutant, cytosolic Nmnat2 variants, suggesting modulation of Nmnat2 subcellular localisation as a means to enhance Nmnat2 half-life and protective capacity<sup>9</sup>.

The Wallerian degeneration phenotype after overexpression in primary culture has not always translated into efficacy *in vivo*<sup>14–16</sup>, and Wallerian degeneration in mouse sciatic nerve takes around four times longer than for injured neurites in primary culture<sup>15,17</sup>. Thus it is important to confirm some of our key primary culture findings *in vivo*. Here we report evidence for a role for ISTID regions in tuning Nmnat2 localisation, turnover and protective capacity in transgenic mice and *Drosophila in vivo*. Using mice expressing wild-type Nmnat2 tagged with a modified yellow fluorescent protein (Nmnat2-Venus) or mutant Nmnat2Δex6-Venus, we find that loss of its central ISTID region leads to a diffuse, non-vesicular localisation of Nmnat2 in peripheral nerves. Confirming our previous observations, we also find evidence for an increased half-life of Nmnat2Δex6-Venus compared to Nmnat2-Venus, suggesting, as the two are closely linked in primary culture<sup>9</sup>, a role for Nmnat2 subcellular localisation in modulating its turnover *in vivo*. Additionally, we confirm that overexpression of a stabilised form of Nmnat2 delays Wallerian degeneration in mouse peripheral nerves. Finally, we show that, while wild-type Nmnat2 fails to protect *Drosophila* olfactory axons, deletion of ISTID regions, transforms Nmnat2 into a highly protective molecule for *Drosophila* axons *in vivo*. These findings suggest modulation of the subcellular localisation of Nmnat2 as a novel means of extending axon survival in ageing and disease.

## Results


**Expression of Nmnat2-Venus and Nmnat2Δex6-Venus in transgenic mice.** In order to study the role of exon 6 – encoded sequences (which we refer to as the “central ISTID region”) in regulating Nmnat2 localisation and turnover *in vivo*, we generated two strains of transgenic mice. Nmnat2-Venus mice (lines 1, 2 and 3 used in this study) express full-length, wild-type Nmnat2 fused to YFP Venus while Nmnat2Δex6-Venus mice express Nmnat2 deficient of exon 6-encoded central ISTID sequences (see Supplementary Figure 1 for an outline of relevant Nmnat2 regions and the position of the exon 6 deletion). Expression in both strains is driven by the Thy1.2 neuron-specific promoter<sup>18</sup>. The presence of the transgene was confirmed by PCR from genomic DNA (Supplementary Figure 2a) and expression of the fusion protein was detectable by Western Blot in total brain as well as in sciatic nerve (Supplementary Figure 2b). Total expression levels in sciatic nerve vary between lines, with line 1 in particular showing notably higher total expression levels than the other Nmnat2-Venus lines, and than Nmnat2Δex6-Venus mice. However, in interpreting this observation, one has to consider the reported finding that Thy1.2-driven transgene expression does not necessarily occur in all neurons and that expression patterns vary widely between lines<sup>18–20</sup>. For this reason, we quantified the percentage of axons expressing the transgene in sciatic nerves from all lines. Cryo-sections of sciatic nerves were stained with FluoroMyelin Red dye and the number of axons exhibiting detectable above-background levels of YFP fluorescence quantified as a percentage of total axons (identified by myelin staining, see Methods for details). As expected, we found considerable differences between lines (Figure 1). In particular, Nmnat2-Venus line 2 showed detectable expression in virtually all axons while expression in other lines was detectable in around 20–50% of axons. Figure 1a also illustrates that expression levels (as judged by YFP intensity) vary between individual axons within the same nerve. Thus we cannot rule out the possibility that some axons might express very low levels of the

transgene below our detection threshold. The transgene was inherited with the expected ratios in all transgenic lines and no overt phenotypic abnormalities were observed up to at least 12 months of age, suggesting that expression of Nmnat2-Venus or Nmnat2Δex6-Venus does not have obvious adverse effects.


**The central ISTID region is necessary for vesicle association *in vivo*.** In primary culture neurons, Nmnat2 associates with Golgi-derived transport vesicles and undergoes fast axonal transport. Loss of the palmitoylation site in its central ISTID region is sufficient to disrupt transport vesicle association and causes Nmnat2 to assume a diffuse, cytosolic distribution<sup>9</sup>. In order to test whether Nmnat2 assumes a vesicular localisation *in vivo*, and whether the central ISTID region is necessary for this, we analysed whole-mount sciatic nerves of Nmnat2-Venus and Nmnat2Δex6-Venus mice. As shown in Figure 2a, clearly identifiable vesicles were observed in sciatic nerve axons from all Nmnat2-Venus lines. In contrast, only diffuse, cytosolic staining was observed in Nmnat2Δex6-Venus axons with no evidence of vesicular association in any of the axons analyzed. Additionally, we confirmed that Nmnat2-Venus vesicles were mobile in peripheral axons through live-imaging of sciatic nerve explants. We observed abundant, bidirectional movement of vesicles in Nmnat2-Venus axons. In contrast, no vesicular structures or movement were observed in Nmnat2Δex6-Venus axons (Figure 2b and Supplementary Movie 1). These results are consistent with a vesicular localisation of Nmnat2-Venus *in vivo* that is dependent on the central ISTID region.

**Loss of the central ISTID region prolongs Nmnat2 half-life *in vivo*.** We previously described emetine chase experiments in HEK 293 cells showing that loss of exon 6-encoded sequences prolonged Nmnat2 half-life considerably<sup>9</sup>. Due to the low level of expression of endogenous Nmnat2 in axons, the limited quality of available antibodies<sup>12</sup> and the potentially compounding issue of expression in non-neuronal cells, the *in vivo* turnover of endogenous Nmnat2 in axons is difficult to study. We therefore used the neuron-specific expression of Nmnat2-Venus in our transgenic mice to test whether loss of the central ISTID region delays Nmnat2 turnover in mouse peripheral nerves. For this, we performed unilateral sciatic nerve lesions and collected sciatic nerves 24 or 72 hours after injury (as shown in Figure 4 and discussed below, Wallerian degeneration does not occur at these time points in axons expressing the transgene in Nmnat2-Venus or Nmnat2Δex6-Venus mice). For quantification, we normalised Nmnat2-Venus levels to βIII-Tubulin levels. For Nmnat2-Venus, the relative level was unchanged 24 hours after cut, but we observed a substantial drop at 72 hours after cut (Figure 3a, c). In contrast, there was essentially no change in Nmnat2Δex6-Venus levels relative to βIII-Tubulin at 72 hours after cut (Figure 3b, c). This suggests that loss of the central ISTID region stabilises Nmnat2-Venus *in vivo*. It is important to note, however, that the observed rate of turnover for wild-type Nmnat2-Venus is considerably slower than that reported for endogenous Nmnat2 in primary culture neurites<sup>1</sup>, as well as for FLAG-tagged Nmnat2 in HEK 293 cells<sup>9</sup>. This is most likely attributable to the YFP tag in the transgenic mice as we found Nmnat2-EGFP to be considerably more stable than FLAG-Nmnat2 in HEK 293 cells (Supplementary Figure 3). Thus, whilst the rate of turnover we observed for Nmnat2-Venus probably does not reflect the true half-life of untagged, wild-type Nmnat2, the fact that Nmnat2Δex6-Venus is considerably more stable than Nmnat2-Venus in cut sciatic nerve nevertheless strongly supports a role for the central ISTID region in tuning Nmnat2 turnover *in vivo*.

**Overexpressed, stabilised Nmnat2 delays Wallerian degeneration *in vivo*.** We next reasoned that the relative overexpression of Nmnat2-Venus, together with its likely stabilisation compared to wild-type Nmnat2, should delay the course of Wallerian degeneration




**Figure 1** | Characterisation of transgene expression in *Nmnat2*-Venus and *Nmnat2*Δex6-Venus mouse lines. (a) Cryostat cross-sections (20 μm thickness) of sciatic nerves of *Nmnat2*-Venus and *Nmnat2*Δex6-Venus mice. YFP fluorescence from transgene expression is shown in green and FluoroMyelin staining is shown in red. In close-up images, white arrows indicate axons that were scored negative for transgene expression and white asterisks indicate axons that were scored positive (note that in line 2 images, virtually no axons were found to be negative for transgene expression). (b) Quantification of the percentage of total axons (identified by FluoroMyelin staining) that showed detectable (above-background) YFP expression in *Nmnat2*-Venus and *Nmnat2*Δex6-Venus mouse sciatic nerves (see Methods). Error bars indicate SEM.



**Figure 2 | The central ISTID region is necessary for vesicle association of Nmnat2-Venus *in vivo*.** (a) Single longitudinal confocal slices of whole-mounted sciatic nerve axons showing numerous clearly identifiable vesicles in nerves from Nmnat2-Venus mice (some highlighted by arrows in each image) compared to exclusively diffuse, cytosolic staining in nerves from Nmnat2Δex6-Venus mice. Two representative images are shown for each line. (b) First frame and corresponding kymograph (time-distance graph) of representative sciatic nerve axon live imaging time series from Nmnat2-Venus and Nmnat2Δex6-Venus mice. Total time represented in kymograph is 2 minutes (240 frames at 2 fps).

in Nmnat2-Venus transgenic mice. Using sciatic nerve lesion experiments, we quantified the percentage of axons that appeared morphologically intact 14 days after injury. In wild-type animals, degeneration starts at 36 hours after cut and is mostly complete by 72 hours<sup>17</sup>. Accordingly, 14 days after cut, axons expressing YFP only (from YFP-H animals) were completely degenerated (Figure 4a, b). In contrast, Nmnat2-Venus animals showed a significant portion of intact axons at this time point. The degree of protection varied between lines, with the largest percentage of intact axons observed in line 2, but all lines analyzed showed a considerable degree of protection (Figure 4a, b). The difference in protective capacity between lines most likely reflects the difference in expression pattern (see Figure 1) as we observed a very strong correlation between the percentage of YFP-positive axons and the percentage of axons protected at 14 days after cut ( $R^2 = 0.9839$ , Figure 4c). These results indicate that overexpression of the relatively stable Nmnat2-Venus fusion protein in peripheral axons is sufficient to afford a significant delay in the time course of Wallerian

degeneration. In previously described *in vitro* experiments we found that loss of exon 6-encoded sequences dramatically enhanced the ability of Nmnat2 to delay neurite degeneration after cut when expressed at low levels in primary culture neurons<sup>9</sup>. In order to test whether loss of this central ISTID region would also increase the protective capacity of Nmnat2 *in vivo*, we compared the ability of Nmnat2Δex6-Venus to delay axon degeneration after sciatic nerve injury in mice to that of Nmnat2-Venus. As for the Nmnat2-Venus lines above, we found substantial protection of Nmnat2Δex6-Venus axons at 14 days after sciatic nerve injury (Figure 4a, b), especially when taking into account the percentage of labelled axons observed (Figures 1 and 4c). As illustrated in Figure 4c, in wild-type Nmnat2-Venus mice, the fraction of axons that express detectable levels of Nmnat2-Venus and the fraction of axons that were morphologically intact 14 days after cut are nearly identical. This suggests very strong protection by wild-type Nmnat2 when stabilised by fusion to YFP Venus. Thus, there was virtually no scope for Nmnat2Δex6-Venus to provide stronger protection than



**Figure 3** | Loss of the central ISTID region stabilises Nmnat2-Venus *in vivo*. (a) Representative Western Blots (cropped) of Nmnat2-Venus expression in sciatic nerves from Nmnat2-Venus line 2 animals 24 or 72 hours after axotomy compared to contralateral, uncut nerve from the same animal. Nmnat2-Venus was detected by the YFP tag.  $\beta$ III-Tubulin was used as loading control. (b) Representative Western Blot (cropped) of Nmnat2 $\Delta$ ex6-Venus expression (detected by YFP tag) in sciatic nerve 72 hours after axotomy compared to contralateral, uncut nerve from the same animal.  $\beta$ III-Tubulin was used as loading control. (c) Quantification of Nmnat2-Venus and Nmnat2 $\Delta$ ex6-Venus turnover in cut sciatic nerve. Expression of Nmnat2-Venus (or Nmnat2 $\Delta$ ex6-Venus) was normalised to  $\beta$ III-Tubulin levels in the same nerve. For presentation purposes, expression levels at 24 and 72 hours after axotomy were normalised to uncut nerve. Error bars indicate SEM. \*\*\* indicates statistically significant difference compared to Nmnat2-Venus ( $p < 0.001$ ,  $n = 3-4$  nerves per line).

wild-type Nmnat2-Venus in this case. Accordingly, we observed a similar maximal protective capacity of Nmnat2 $\Delta$ ex6-Venus compared to wild-type Nmnat2-Venus (Figure 4). This means that the existing Nmnat2-Venus and Nmnat2 $\Delta$ ex6-Venus mouse lines did not allow us to adequately test the hypothesis that loss of the central ISTID region boosts the axon protective capacity of Nmnat2 *in vivo*.


**Loss of ISTID regions enhances protective capacity of Nmnat2 in *Drosophila* axons.** In order to clarify whether loss of central ISTID regions can improve axon protection by Nmnat2 *in vivo*, we tested the protective capacities of wild-type and mutant Nmnat2 isoforms, lacking any tags that could stabilise the protein, in *Drosophila* axons. We previously found that a series of deletion mutants (Nmnat2 $\Delta$ 32,  $\Delta$ 43,  $\Delta$ 69 and  $\Delta$ 82 – see Supplementary Figure 1 for an outline of the location of the deletion in each mutant) based on human Nmnat2<sup>21</sup> have greatly increased axon protective capacity compared to wild-type Nmnat2 in mouse primary culture neurites<sup>9</sup>. The deletions in these mutants span parts of the central isoform-specific targeting and interaction domain (ISTID)<sup>13</sup> region of Nmnat2 and include part ( $\Delta$ 32) or all of the exon 6 – encoded region ( $\Delta$ 43,  $\Delta$ 69 and  $\Delta$ 82), which is essential for targeting Nmnat2 to vesicles<sup>9</sup>. We expressed wild-type and each of these mutant Nmnat2 isoforms in flies in which a subset of antennal olfactory receptor neuron (ORN) axons were labelled by GFP expression (*OR22a-Gal4*, *UAS-mCD8::GFP*)<sup>22,23</sup>. Axotomy was induced by bilateral third antennal segment ablation and the number of remaining GFP-positive axons was scored 7, 14 and 30 days after axotomy. We previously found non-stabilised wild-type Nmnat2 to be only weakly protective and to require strong overexpression in order to achieve moderate

protection in mouse primary culture neurites<sup>19</sup>. Consistent with this and with other previous work<sup>24</sup>, we found that expression of untagged human Nmnat2 in *Drosophila* did not preserve ORN axons at any of the time points analysed (Figure 5). In contrast, flies expressing the deletion mutants showed strong preservation of ablated axons 7 and 14 days after axotomy, with a substantial proportion being protected until 30 days after antennal ablation (Figure 5). These findings support a role for the central ISTID region in modulating Nmnat2 axon protective capacity *in vivo*. Moreover, these data also suggest that the molecular mechanisms by which loss of the central ISTID region boosts Nmnat2 axon protective capacity are conserved from *Drosophila* to mammals.

## Discussion

We previously reported that loss of exon 6-encoded sequences boosts the protein stability and axon protective capacity of Nmnat2 *in vitro*<sup>9</sup>. The results presented here confirm that a similar mechanism operates *in vivo*. We find that deletion of the central, exon 6-encoded ISTID region causes loss of vesicle association and delays the turnover of Nmnat2-Venus in mouse peripheral axons. Moreover, untagged mammalian Nmnat2, which is not protective in *Drosophila* ORN axons<sup>24</sup> and provided only weak, transient protection in *Drosophila* wing axons<sup>25</sup>, can be transformed into a highly protective protein for *Drosophila* axons through deletions of its central ISTID region. These findings are an important confirmation illustrating the possibility of turning endogenous Nmnat2 into a highly protective molecule to address axon degeneration in a mammalian system.

The strong protective effect observed with Nmnat2-Venus alone meant that our mouse lines did not allow us to directly compare the protective capacities of wild-type and central ISTID – deficient




**Figure 4 | Strong axon protection by Nmnat2-Venus and Nmnat2Δex6-Venus after sciatic nerve axotomy.** (a) Representative images of Richardson stained semi-thin (500 nm) sections of 14-day cut or uncut sciatic nerves of YFP-H, Nmnat2-Venus and Nmnat2Δex6-Venus mice. (b) Quantification of percentage intact axons in uncut and 14-day cut sciatic nerves from YFP-H (YFP), Nmnat2-Venus (line 1, 2 and 3) and Nmnat2Δex6-Venus (Δex6) mice. Error bars indicate SEM. (c) Graph showing correlation between percentage of axons identified as labelled in sciatic nerve cryo-sections and percentage of axons preserved in sciatic nerves of the same animals 14 days post-axotomy. Line represents best-fit linear regression, error bars show SEM. The relevant transgenic line is indicated for each data point.

Nmnat2 *in vivo*. While it is possible that loss of the central ISTID region does not improve Nmnat2 – mediated axon protection in mouse peripheral axons, it appears more likely that the strong over-expression and enhanced stability of Nmnat2-Venus relative to endogenous Nmnat2 masks any potential benefit of the deletion of the central ISTID. Due to the high steady-state level and longer half-life relative to endogenous Nmnat2, levels of Nmnat2-Venus remain above the threshold required for axon maintenance, even when its relative levels drop between 24 and 72 hours after cut. This interpretation is further supported by the observed effect of deletion of the central ISTID region on the stability of Nmnat2-Venus, which would likely translate into a higher protective capacity under conditions of lower expression. Finally, the strong increase in protective capacity of mammalian Nmnat2 ISTID deletion mutants in *Drosophila* olfactory receptor neuron axons further supports a role for the central ISTID region in tuning Nmnat2-mediated axon protection.

Even though *Drosophila* has only a single Nmnat isoform, our results suggest that the ISTID-dependent destabilisation or mislocalisation mechanism observed for mammalian Nmnat2 is conserved

across species. Mammalian Nmnat2 was previously shown to be able to substitute for dNmnat to some extent in *Drosophila*<sup>25</sup>. Additionally, Highwire, an E3 ubiquitin ligase proposed to regulate turnover and protective capacity of dNmnat, also affects the stability of mammalian Nmnat2 in *Drosophila* axons<sup>11</sup>. Here we find that protection of *Drosophila* ORN axons by mammalian Nmnat2 is boosted by loss of central ISTID regions, which stabilises Nmnat2 in mammalian nerves and greatly enhances axon protection in mammalian primary culture neurons. These results indicate that the mechanisms that mediate the delayed degeneration resulting from deletion of Nmnat2 central ISTID sequences in mammalian primary culture axons are conserved in *Drosophila*.

Confirming our primary culture observations, loss of the central ISTID region does not interfere with the entry of Nmnat2-Venus into long peripheral axons. While we cannot completely exclude the possibility that the YFP tag somehow mediates axon entry, this suggests that long-range vesicle-mediated transport might not be necessary to deliver Nmnat2 into axons, even *in vivo*. Other soluble proteins have been reported to be trafficked into axons by transient attachment to



**Figure 5** | *Nmnat2* deletion mutants with strongly increased protective capacity in *Drosophila* axons. (a) Representative images of GFP-positive (OR22a<sup>+</sup>) axons in antennal lobes of flies expressing wild-type or mutant human *Nmnat2* (wt – full-length *Nmnat2*, Δ32 – *Nmnat2*Δ32, Δ43 – *Nmnat2*Δ43, Δ69 – *Nmnat2*Δ69, Δ82 – *Nmnat2*Δ82). Images were taken 7, 14 and 30 days after bilateral antennal ablation as indicated. (b) Quantification of number of intact GFP-expressing axons in antennal lobe of flies expressing wild-type or mutant *Nmnat2* isoforms scored 7, 14 and 30 days post-ablation. Age-matched untreated flies were used as controls. Error bars indicate SEM.  $n \geq 3$  antennal lobes per genotype and time point.

the transport machinery<sup>26</sup>. This of course raises the question as to the functional role of *Nmnat2* vesicle association in axons. One possibility, consistent with our results, is that vesicle-association helps to ensure rapid removal and turnover of *Nmnat2*. However, given the absence of adverse effects observed in any of our transgenic lines overexpressing a stabilised, mislocalised form of the protein, the importance of *Nmnat2* instability to the normal functioning of axons is presently unclear. It is, however, important to note that expression of *Nmnat2*-Venus in these mice does not commence until the post-natal period, masking any potential effects of a stabilised *Nmnat2* on developmental processes. Additionally, rapid removal of *Nmnat2* after an injury will of course facilitate rapid de- and re-generation of axons, allowing quick functional recovery, which remains to be tested in our *Nmnat2*Δex6-Venus mice.

In summary, our results support a role for the central ISTID region in tuning *Nmnat2* localisation, stability and protective capacity *in vivo*. Loss of the central ISTID region transforms *Nmnat2* from an unstable, vesicle-associated protein that is nevertheless critical for

preventing spontaneous degeneration of unharmed axons, into a widely distributed, stabilised protein that can robustly protect axons after injury. Understanding the mechanisms behind this phenomenon could uncover novel avenues for axon protection through modulation of endogenous *Nmnat2*.

## Methods

**Mouse strains.** All animal work was carried out in accordance with the Animals (Scientific Procedures) Act, 1986, under Project License 80/2254. C57BL/6Jab mice (BSU, Babraham Institute) were used for breeding. YFP-H mice (exact strain name: B6.Cg-TgN(Thy1-YFP-H)2Jrs) used as controls were heterozygotes.

**Generation of transgenic mice.** Transgene expression in *Nmnat2*-Venus and *Nmnat2*Δex6-Venus was driven by the *Thy1.2*-promoter that has previously been described for the generation of neuron-specific transgenic mouse lines<sup>18–20</sup>. The coding sequences of full-length *mus musculus* *Nmnat2* or the *Nmnat2*Δex6 deletion mutant<sup>9</sup> were C-terminally fused to YFP Venus<sup>27</sup> (kindly provided by Dr. Llewelyn Roderick, Babraham Institute) and inserted into the *Thy1.2* expression vector (a kind gift from Prof. Thomas Misgeld, TU Munich). Transgenic mice were generated by pronuclear injection (Babraham Institute Gene Targeting Facility) into C57BL6/CBA





F1 zygotes. For *Nmnat2-Venus* mice, nine potential founders were identified and four transgenic lines (1, 2, 3 and 8) were maintained as heterozygotes by crossing to C57BL/6J B6. Lines 1, 2 and 3 were used for experiments described in this study. For *Nmnat2Δex6-Venus*, a single founder was identified and one transgenic line was established, maintained by crossing to C57BL/6J B6 and used for this study.

**PCR genotyping.** PCR primers were designed to amplify a region of *Nmnat2* from the start of exon 9 to the end of exon 10 (fwd: 5'-atggaagtgtgttggggac-3'; rev: 5'-ctgctctgttgagctgac-3'). This resulted in a 300 bp fragment for endogenous *Nmnat2* and a 170 bp fragment indicating the presence of *Nmnat2-Venus* or *Nmnat2Δex6-Venus* as these constructs lack the intervening intron.

**Collection of brains and nerves for western blot analysis.** Brain and sciatic nerves were dissected rapidly from freshly killed mice and frozen immediately by immersion in liquid nitrogen. For lysis, tissue was allowed to thaw on ice and 500 μl (for brain halves) or 50 μl (for sciatic nerve) TG lysis buffer was added (20 mM Tris pH 7.5, 137 mM NaCl, 1 mM EGTA, 1% TritonX-100, 10% glycerol, 1.5 mM MgCl<sub>2</sub>, 50 mM NaF, 1 mM Na<sub>2</sub>VO<sub>4</sub> and protease inhibitor mix). Tissue was disrupted by sonication for 3 times 6 seconds on ice. Unbroken cells were removed by spinning samples at 13 000 rpm for 10 minutes at 4°C and transferring the supernatant to a new tube. Sciatic nerve samples were diluted 1:1 and brain samples 1:4 into 2× SDS sample buffer prior to SDS PAGE and Western Blot analysis.

**Western blotting.** SDS-PAGE analysis and Western Blotting analysis were performed as described<sup>128</sup>. Anti-GFP antibody (Abcam ab290) was used at 1:2000, anti-βIII-Tubulin (TUJ1, Covance) was used at 1:15 000 and HRP-conjugated anti-mouse and anti-rabbit IgG (BioRad) were used at 1:2000.

**Tissue cryo-sectioning and staining.** Nerves from freshly killed animals were dissected rapidly and fixed by immersion into cold 4% PFA for at least 3 days, washed 3 times in 0.1 M PBS and cryopreserved in 30% sucrose supplemented with 0.1% sodium azide for at least 3 days at 4°C. Tissue was sectioned on a Leica CM1850 cryostat. Typical section thickness was 20 μm for nerve cross-sections. Sections were transferred onto Superfrost plus slides (VWR), allowed to dry and permeabilised in PBS with 0.2% Triton-X 100 for 30 minutes at room temperature. Where indicated, sections were then stained with FluoroMyelin Red stain according to manufacturer's instructions (Life Technologies). Stained sections were imaged on an Olympus FV1000 point scanning confocal microscope (IX81 microscope, 60 × 1.35 NA plan super apochromat and 40× plan fluorite 1.3 NA objectives). For quantification of the percentage of axons expressing the transgene, the total number of axons in a field was determined by counting FluoroMyelin - stained myelin rings. Axons were scored as positive for transgene expression if above-background levels of YFP fluorescence were detectable in the axoplasm (see Figure 1a for examples of axons scored as positive and negative for transgene expression). Six representative fields of view, each of which contained about 100 axons, were counted and averaged per animal for a total of n = 4 animals per line.

**Nerve whole-mount.** For longitudinal sciatic nerve whole-mount preparations, freshly dissected sciatic nerves were gently stretched during fixation using insect pins. Nerves were fixed in 4% PFA for at least 2 days at 4°C. Fixed nerves were then washed three times in 0.1 M PBS, transferred to a slide and a coverslip was mounted using Vectashield (Vector Laboratories).

**Semi-thin sectioning and staining.** Sciatic nerves were fixed, embedded and sectioned to 500 nm thickness as previously described<sup>29</sup> and stained using Richardson's stain (0.5% Methylene Blue, 0.5% Azure II in 0.5% sodium tetraborate). Stained sections were visualised on a brightfield microscope equipped with a colour camera (Olympus BX41/Micropublisher 3.3 system, 100 × 1.4 NA objective).

**Axonal transport imaging of sciatic nerve explants.** Imaging of axonal transport in sciatic nerve explants of *Nmnat2-Venus* and *Nmnat2Δex6-Venus* mice was performed on an Olympus Cell<sup>R</sup> imaging system (IX81 microscope, Hamamatsu ORCA ER camera, 100 × 1.45 NA apochromat objective). During imaging, nerves were maintained in oxygenated Neurobasal-A medium at 37°C in an environment chamber (Solent Scientific). Images were captured at 2 frames per second. Following imaging, individual axons were straightened and kymographs generated using ImageJ software plugins (Rasband, W.S., ImageJ, NIH, Bethesda, Maryland, USA, <http://imagej.nih.gov/ij/>, 1997–2013).

**Construction of *Nmnat2* vectors and transgenic flies.** *Nmnat2* deletion mutants (Δ32, Δ43, Δ69, and Δ82)<sup>21</sup> were a gift from Prof. Giulio Magni (Ancona, Italy). The ORF of human *Nmnat2* (wild-type or deletion mutant) was amplified using the oligonucleotides 5'-AGTCAAGATCTACCCACTGACCGAGACCACCAAG-ACC-3' (5' primer with Kozak sequence and 5' BglII site) and 5'-GGATCTCG-AGCTAGCCGGAGGCATTGATGTACAGC-3' (3' primer with XhoI site), cloned into a modified pJRC-MUH plasmid (Addgene plasmid 26213; modified by cutting pJRC-MUH with SbfI and SphI, removing 128 bp, including one 5× UAS site), and confirmed by DNA sequencing. *Drosophila* embryo injections were performed as a fee-for-service (BestGene, Inc., Chino Hills, CA) and transgenic lines established in the attP40 strain (estimated cytosine 25C7) were confirmed for the presence of the wild-type or mutant transgene by sequencing of PCR product.

**Antennal injury and axon quantification.** *OR22a-Gal4<sup>22</sup>* and *pUAS-mCD8::GFP* were combined with each *Nmnat2* construct. We induced antennal injury using a modification of a previously described protocol<sup>23</sup>. Newly eclosed adult flies were aged for 7 days at 25°C before ablating both third antennal segments (bilateral injury). Injured flies were aged at 25°C for the indicated time (7, 14, or 30 days) before dissecting and fixing the brain. Axonal integrity was scored by counting the number of intact GFP positive axons present.

**Drosophila confocal microscopy.** Samples were mounted in Vectashield antifade reagent and viewed on a III Everest Spinning disk confocal microscope (40×, 1.3 NA, Plan Apochromat objective). The entire antennal lobe was imaged in 0.27 μm steps for each sample for scoring axonal integrity.

**Statistical analysis.** Data presentation and statistical analysis were performed with Prism 5 (GraphPad) and SPSS Statistics 20 (IBM) software.

- Gilley, J. & Coleman, M. P. Endogenous *Nmnat2* Is an Essential Survival Factor for Maintenance of Healthy Axons. *PLoS Biol* **8**, e1000300 (2010).
- Gilley, J., Adalbert, R., Yu, G. & Coleman, M. P. Rescue of Peripheral and CNS Axon Defects in Mice Lacking NMNAT2. *J Neurosci* **33**, 13410–13424 (2013).
- Mack, T. G. *et al.* Wallerian degeneration of injured axons and synapses is delayed by a *Ube4b/Nmnat* chimeric gene. *Nat Neurosci* **4**, 1199–206 (2001).
- Babetto, E. *et al.* Targeting NMNAT1 to axons and synapses transforms its neuroprotective potency in vivo. *J Neurosci* **30**, 13291–304 (2010).
- Sasaki, Y., Vohra, B. P. S., Baloh, R. H. & Milbrandt, J. Transgenic mice expressing the *Nmnat1* protein manifest robust delay in axonal degeneration in vivo. *J Neurosci* **29**, 6526–34 (2009).
- Feng, Y. *et al.* Overexpression of *Wld(S)* or *Nmnat2* in mauthner cells by single-cell electroporation delays axon degeneration in live zebrafish. *J Neurosci Res* **88**, 3319–27 (2010).
- Yan, T. *et al.* *Nmnat2* delays axon degeneration in superior cervical ganglia dependent on its NAD synthesis activity. *Neurochem Int* **56**, 1–6 (2009).
- Ljungberg, M. C. *et al.* CREB-activity and *nmnat2* transcription are down-regulated prior to neurodegeneration, while NMNAT2 over-expression is neuroprotective, in a mouse model of human tauopathy. *Hum Mol Genet* **21**, 251–67 (2012).
- Milde, S., Gilley, J. & Coleman, M. P. Subcellular Localization Determines the Stability and Axon Protective Capacity of Axon Survival Factor *Nmnat2*. *PLoS Biol* **11**, e1001539 (2013).
- Zhai, Q. *et al.* Involvement of the ubiquitin-proteasome system in the early stages of wallerian degeneration. *Neuron* **39**, 217–25 (2003).
- Xiong, X. *et al.* The Highwire Ubiquitin Ligase Promotes Axonal Degeneration by Tuning Levels of *Nmnat* Protein. *PLoS Biol* **10**, e1001440 (2012).
- Babetto, E., Beirowski, B., Russler, E. V., Milbrandt, J. & DiAntonio, A. The *Phr1* ubiquitin ligase promotes injury-induced axon self-destruction. *Cell Rep* **3**, 1422–9 (2013).
- Lau, C. *et al.* Isoform-specific targeting and interaction domains (ISTIDs) in human nicotinamide mononucleotide adenylyltransferases (NMNATs). *J Biol Chem* **3**, 18868–18876 (2010).
- Araki, T., Sasaki, Y. & Milbrandt, J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. *Science* **305**, 1010–3 (2004).
- Conforti, L. *et al.* NAD(+) and axon degeneration revisited: *Nmnat1* cannot substitute for *Wld(S)* to delay Wallerian degeneration. *Cell Death Differ* **14**, 116–27 (2007).
- Yahata, N., Yuasa, S. & Araki, T. Nicotinamide mononucleotide adenylyltransferase expression in mitochondrial matrix delays Wallerian degeneration. *J Neurosci* **29**, 6276–84 (2009).
- Beirowski, B. *et al.* The progressive nature of Wallerian degeneration in wild-type and slow Wallerian degeneration (*Wlds*) nerves. *BMC Neurosci* **6**, 6 (2005).
- Caroni, P. Overexpression of growth-associated proteins in the neurons of adult transgenic mice. *J Neurosci Methods* **71**, 3–9 (1997).
- Misgeld, T., Kerschensteiner, M., Bareyre, F. M., Burgess, R. W. & Lichtman, J. W. Imaging axonal transport of mitochondria in vivo. *Nat Methods* **4**, 559–61 (2007).
- Feng, G. *et al.* Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. *Neuron* **28**, 41–51 (2000).
- Brunetti, L., Di Stefano, M., Ruggieri, S., Cimadamore, F. & Magni, G. Homology modeling and deletion mutants of human nicotinamide mononucleotide adenylyltransferase isozyme 2: new insights on structure and function relationship. *Protein Sci* **19**, 2440–50 (2010).
- Dobritsa, A. A., Van der Goes van Naters, W., Warr, C. G., Steinbrecht, R. A. & Carlson, J. R. Integrating the molecular and cellular basis of odor coding in the *Drosophila* antenna. *Neuron* **37**, 827–41 (2003).
- MacDonald, J. M. *et al.* The *Drosophila* cell corpse engulfment receptor *Draper* mediates glial clearance of severed axons. *Neuron* **50**, 869–81 (2006).
- Avery, M. A., Sheehan, A. E., Kerr, K. S., Wang, J. & Freeman, M. R. *Wld S* requires *Nmnat1* enzymatic activity and N16-VCP interactions to suppress Wallerian degeneration. *J Cell Biol* **184**, 501–13 (2009).
- Fang, Y., Soares, L., Teng, X., Geary, M. & Bonini, N. M. A Novel *Drosophila* Model of Nerve Injury Reveals an Essential Role of *Nmnat* in Maintaining Axonal Integrity. *Curr Biol* **22**, 590–595 (2012).



26. Scott, D. A., Das, U., Tang, Y. & Roy, S. Mechanistic logic underlying the axonal transport of cytosolic proteins. *Neuron* **70**, 441–54 (2011).
27. Nagai, T. *et al.* A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications. *Nat Biotechnol* **20**, 87–90 (2002).
28. Gilley, J. *et al.* Age-dependent axonal transport and locomotor changes and tau hypophosphorylation in a “P301L” tau knockin mouse. *Neurobiol Aging* **33**, 621.e1–621.e15 (2012).
29. Adalbert, R. *et al.* A rat model of slow Wallerian degeneration (Wlds) with improved preservation of neuromuscular synapses. *Eur J Neurosci* **21**, 271–7 (2005).

## Acknowledgements

We would like thank Robert Adalbert for helpful discussion, Jon Gilley for valuable comments on the manuscript, Simon Walker for assistance with live imaging and Llewelyn Roderick, Giulio Magni and Thomas Misgeld for donation of plasmid constructs.

## Author contributions

Conceived and designed the experiments: S.M., A.N.F., M.R.F., M.P.C. Performed the experiments: S.M., A.N.F. Analysed the data: S.M., A.N.F. Prepared the figures: S.M. Wrote the paper: S.M., A.N.F., M.R.F., M.P.C.

## Additional information

**Financial disclosure:** This work was funded by a Medical Research Council (MRC; <http://www.mrc.ac.uk>) studentship (SM), Biotechnology and Biological Sciences Research Council (<http://www.bbsrc.ac.uk>) Institute Strategic Programme Grant (MPC) and NIH RO1 NS059991 (MRF). MRF is an Early Career Scientist with the Howard Hughes Medical Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Supplementary information** accompanies this paper at <http://www.nature.com/scientificreports>

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Milde, S., Fox, A.N., Freeman, M.R. & Coleman, M.P. Deletions within its subcellular targeting domain enhance the axon protective capacity of Nmnat2 *in vivo*. *Sci. Rep.* **3**, 2567; DOI:10.1038/srep02567 (2013).



This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported license. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/3.0>